Similarly, palbociclib has proven activity in Rb1-deficient prostate cancer cells [26] and hepatocellular carcinoma cells in vitro, in which some activity in Rb1-deficient cells may be compensated by related proteins such as p107 [27]. Here, RB1 is linked to prostate cancer.